share_log

Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application

Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application

Bio-Path已啓動治療項目,開發BP1001-A用於肥胖和相關代謝性疾病,該項目標誌着DNAbilize技術首次應用於非癌症應用的開發。
Benzinga ·  10/08 07:08

Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application

Bio-Path已啓動治療項目,開發BP1001-A用於肥胖和相關代謝性疾病,該項目標誌着DNAbilize技術首次應用於非癌症應用的開發。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論